Skip to main content
Menu

Posts tagged with "Drug Industry History"

  • Drug Assays

    Why Does Screening Work At All? (Free Business Proposal Included!)

    I’ve been meaning to get around to a very interesting paper from the Shoichet group that came out a month or so ago in Nature Chemical Biology. Today’s the day! It examines the content of screening libraries and compares them to what natural products generally look like, and they turn up some surprising things along… Read More
  • Business and Markets

    How Much Does the Drug Industry Spend on Marketing?

    Anyone who defends the pharmaceutical industry has to be ready to hear, over and over and over, about how much it spends on sales and marketing versus R&D. This is thought to be a telling point about where the priorities really are. I’ve addressed this one several times, and my best response is to point… Read More
  • Drug Industry History

    Jargon Will Save Us All

    Moore’s Law: number of semiconductors on a chip doubling every 18 months or so, etc. Everyone’s heard of it. But can we agree that anyone who uses it as a metaphor or perscription for drug research doesn’t know what they’re talking about? I first came across the comparison back during the genomics frenzy. One company… Read More
  • Business and Markets

    GSK’s Getting Better. Just Ask the CEO.

    There are some interesting statements from GlaxoSmithKline CEO Andrew Witty here at Reuters. He admits that morale was completely in the scupper around the place a few months ago, which certainly seems to be true, but says that they’re turning things around. To that point, remember all that stuff a few years ago about how… Read More
  • Drug Development

    The View From Pfizer’s Corner Offices

    There’s a good article from Lee Howard up at The Day (the New London/Groton newspaper) on the changes going on at Pfizer. It’s the story according to management, though, which is worth having for its compare-and-contrast uses: Despite the looming uncertainty, according to company spokesmen, the new research structure has added energy an… Read More
  • Business and Markets

    CafePharma Will Now Approach The Bench

    Here’s an interesting situation for you: according to IguanaBio, a shareholder lawsuit over the failed Vytorin ENHANCE clinical trial (that’s caused Schering-Plough and Merck so much grief) is going to use posts on CafePharma as evidence. That will be worth watching. CafePharma’s message boards have been described (accurately, I&# Read More
  • Business and Markets

    Akt and Mek, But Not PDQ

    Well, the ASCO meeting has been roaring along, with dozens of press releases coming out. (Go to Google News and type that acronym in if you want to get the full experience). They range from the pretty-interesting to the despair-inducing, but one bit of news struck me as particularly worth noting. That’s the early-stage deal… Read More
  • Drug Development

    The NIH Takes the Plunge

    The NIH has announced that they’re going to start up a preclinical drug discovery effort to address rare diseases. I find this interesting for several reasons. For one thing, it’s worth a try for conditions where no company has seen a way to fund research, and there are quite a few of them. Treating rare… Read More
  • Business and Markets

    San Francisco Biotech: Holding Up, or Not?

    I’ve got a piece coming up today at The Atlantic Monthly‘s business site on the state of the biotech industry out in the Bay Area. Since the Genentech takeover fight broke out, a persistent theme in the comments here (and in e-mail that I’ve received) has been how well the industry is holding up out… Read More
  • Drug Industry History

    Book Review Department

    For those who are interested, I have a review up at Nature Biotechnology of Reasonable Rx: Solving the Drug Price Crisis, a book that proposes an. . .interesting solution for reworking the drug industry. And as Fate would have it, I also have a review in the latest issue of Nature Chemistry of Drug Truths: Read More
...303132...